Melacare PLUS

Quick links to important sections

Melacare PLUS

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Melacare PLUS

Quick Facts

Property Description
Active Ingredients Hydroquinone, Tretinoin, and Mometasone Furoate
Form Topical Cream (Fixed-Dose Combination)
Pharmacological Class Depigmenting Agent, Retinoid, and Corticosteroid Combination
Route of Administration External use only (Cutaneous)
Origin Primarily Synthetic and Derivative Compounds

What Type of Medicine is Melacare PLUS?

Melacare PLUS is defined as a specialized fixed-dose combination dermatological medication, typically presented as a topical cream intended for external use only. It is classified as a triple combination therapy because it integrates three pharmacologically distinct active ingredients into a single preparation. The unique feature of this product is its combined approach, utilizing a depigmenting agent, a potent anti-inflammatory corticosteroid, and a regulating retinoid. Triple combination creams have been used in treating severe skin discoloration disorders, highlighting their established role in clinical settings. This indicates that the combined formulation is a recognized approach for specific skin conditions.

What is the Composition of Melacare PLUS?

The composition features the active substances: Hydroquinone, Tretinoin, and Mometasone Furoate, which are predominantly synthetic in origin, blended into an emollient cream base. Hydroquinone acts as a melanin synthesis inhibitor, while Tretinoin accelerates the renewal of surface skin cells. The inclusion of Mometasone Furoate, a medium-potency corticosteroid, helps to minimize the local irritation often associated with retinoid and hydroquinone application. This indicates the formula is intentionally balanced to mitigate potential discomfort, a factor critical for user compliance in prolonged topical treatments.

What is the General Purpose of this Combination Therapy?

The overarching goal of this triple combination therapy is to promote a noticeably lighter and more uniform appearance, offering a distinct advantage over single-ingredient products. It is clinically recognized for use in patients experiencing severe forms of hyperpigmentation, such as persistent dark patches on the skin. By coordinating melanin synthesis inhibition with enhanced skin cell renewal and local inflammation control, the formulation is engineered to address the multiple biological factors underlying skin discoloration, leading to comprehensive and sustained pigment reduction.

Regulatory References

  1. Mometasone Furoate Professional Monograph (DailyMed, NIH)

What side effects are possible with Melacare PLUS?

Possible Side Effects and Safety Information

The official safety profile for this triple combination cream is categorized by the types, frequency, and severity of documented adverse reactions, as established in government regulatory prescribing documents.

Adverse Reaction Scope Classification Summary (Based on Regulatory Documents)
Frequency-Classified Reactions Common local effects include erythema (redness), desquamation (peeling), burning, and dryness. Uncommon reactions may include pruritus (itching), acne, and paresthesia (tingling).
System-Organ Classes Effects primarily involve Skin and Subcutaneous Tissue Disorders. Potential systemic absorption of the corticosteroid component may affect Endocrine Disorders (e.g., HPA axis suppression).
Serious Adverse Reactions Clinically significant documented risks include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing's syndrome, linked to systemic corticosteroid absorption. Exogenous Ochronosis, a gradual blue-black skin darkening, is a rare but documented risk associated with hydroquinone.
Safety-Related Constraints The cream is officially Contraindicated in individuals with known hypersensitivity to any component. Pediatric patients are noted as being more susceptible to systemic toxicity, and the use of tretinoin involves specific Pregnancy considerations.
Time-Related Patterns Local irritation, such as burning and peeling, is often documented as being more frequent at the initiation of therapy. Risks such as skin atrophy and striae (stretch marks) are associated with prolonged use.

Connection to the Overall Safety Profile

This regulatory classification structures the understanding of the medicine's risks by clearly distinguishing frequent, localized skin reactions from rare, serious systemic safety outcomes. The official documentation ensures that potential risks—from common irritation at the start of treatment to risks associated with long-term exposure or specific patient populations—are formally categorized according to standard government health authority requirements.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of this triple combination topical cream is classified into two main risk areas based on official regulatory documents. Acute overdose, often from excessive topical application, may result in severe local hyper-reactions, including profound erythema (redness), peeling, and a burning or stinging sensation.


Severe Systemic Risk and Monitoring

The most serious potential outcome is linked to chronic, excessive use of the Mometasone Furoate component. Prolonged or large-area application increases the risk of systemic absorption, which can lead to Hypothalamic-pituitary-adrenal (HPA) axis suppression and the clinical signs of Hypercortisolism (Cushing's Syndrome). For this reason, regulatory guidance mandates periodic monitoring of HPA axis function in cases of suspected systemic toxicity. Pediatric patients are identified as being more susceptible to this systemic risk.


Emergency Actions

Situation Required Action (Regulatory Statement)
Accidental Ingestion Seek immediate medical attention and contact a Poison Control Center immediately.
Severe Local Reaction Urgent medical consultation is required if severe local skin reactions persist or worsen significantly.

No specific antidote is known for this combination product; therefore, management remains symptomatic and supportive.

Therapeutic Uses of Melacare PLUS

What Melacare PLUS Treats: Main Uses and Benefits


The primary therapeutic domain for this combination cream is the management of challenging pigmentary disorders. Its use is considered relevant for the management of moderate-to-severe melasma of the face. This approach is applied when supportive symptom management is appropriate for conditions involving episodic or fluctuating manifestations of hyperpigmentation.

This medication is commonly used to manage the symptom clusters associated with melasma and Post-Inflammatory Hyperpigmentation (PIH). It helps address symptoms that create noticeable physiological strain, primarily by providing a comprehensive approach to pronounced and recurrent discoloration. The therapeutic relevance is in addressing uneven skin tone and the presence of persistent dark patches on the face.

The cream supports managing symptoms related to inflammatory or irritative states often linked to pigment changes, which contributes to improving comfort during difficult episodes. This may assist with maintaining a sense of stability in skin appearance.


Quick Fact: Relief for Pigmentary Discomfort

Symptom Category Therapeutic Goal
Persistent Dark Patches Helps to manage the visibility of the discoloration.
Uneven Skin Tone Supports the improvement of overall skin uniformity.
Associated Irritation Contributes to easing symptoms linked to inflammatory states.

Eligibility and Restrictions for Use

The eligibility criteria for this triple-combination topical cream (containing Hydroquinone, Tretinoin, and Mometasone Furoate) are governed by the restrictions associated with its active ingredients, as defined in official regulatory documents.

Populations and Conditions Prohibited from Use

Classification Population or Condition
Contraindicated Individuals with known hypersensitivity to any of the active ingredients (Hydroquinone, Tretinoin, Mometasone Furoate) or to any excipient, such as sulfites (which may cause severe allergic reactions).
Not Recommended Pregnant women, due to the teratogenic potential of the retinoid component.
Not Established Pediatric patients under 18 years of age, as safety and efficacy have not been formally established.

Eligibility and Conditional Use

The medicine is officially established for use by adults (18 years and older). However, its use is subject to several restrictions:

  • Reproductive Status: Women of child-bearing potential must use effective contraception during the course of therapy. Use while breastfeeding requires caution, as it is not confirmed if the components pass into human milk.
  • Comorbidities: Use is limited by conditions that increase systemic risk, such as factors predisposing a patient to Hypothalamic-Pituitary-Adrenal (HPA) axis suppression from the corticosteroid component. The cream should be used with caution on pre-existing eczematous skin due to the risk of severe irritation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Melacare PLUS Cream is a topical combination of Hydroquinone, Mometasone, and Tretinoin. Due to its external application, the majority of documented interaction concerns relate to additive local effects on the skin.


Pharmacodynamic and Topical Interactions

Official regulatory information emphasizes caution regarding additive irritation or drying effects when the cream is used alongside other topical agents.

Interaction Type Substances to Use with Caution/Avoid
Additive Irritation/Drying Sulphur, Resorcinol, Salicylic acid, Benzoyl peroxide, medicated soaps, cleansers, or cosmetics with abrasive or peeling actions.
Topical Excipients Products with high alcohol content, astringents, spices, or lime.

These restrictions aim to prevent severe local adverse skin reactions, which are the primary documented interactions for this formulation.


Systemic Pharmacokinetic Considerations

While systemic absorption from topical use is low, the active components, Tretinoin and Mometasone, are known to be metabolized by the CYP3A enzyme family. Therefore, a theoretical potential exists for strong systemic CYP3A inhibitors to increase the low-level systemic exposure of these components.

No explicit timing-based separation rules or systemic drug-drug contraindications are documented in the regulatory labeling for this topical cream. Caution is generally advised for use in patients with pre-existing liver or kidney health issues.

Mechanism of Action

How Melacare PLUS Works

The mechanism of action involves three active ingredients, each targeting distinct physiological processes to modulate pigment formation and local cellular activity. The components interact with multiple levels of the melanogenesis and epidermal turnover pathways.

Inhibition of Melanin Synthesis

One active ingredient functions as an enzyme inhibitor of tyrosinase within melanocytes, acting on the melanogenesis pathway. Tyrosinase is required for the conversion of L-tyrosine into the pigment, melanin. By blocking this enzymatic step, the rate of pigment production is actively altered, resulting in a diminished level of melanin present in the skin over time.

Accelerated Epidermal Turnover

The second active ingredient acts as a retinoid receptor agonist that engages specific receptors within keratinocytes, altering gene expression. This action accelerates the differentiation and proliferation of epidermal cells, significantly increasing the rate of cell renewal and shedding (desquamation). This increase in shedding promotes the removal of pigment-laden cells from the surface layers.

Modulation of Local Inflammation

The final active ingredient is a glucocorticoid receptor agonist that binds to receptors in immune and inflammatory cells. This action suppresses the release and activity of key inflammatory mediators, such as cytokines. This mechanism modulates the local inflammatory pathway and limits inflammatory signals that can activate melanocytes.

Dosage and Administration Information

How to Use Melacare PLUS: Official Administration Guidelines

The general principle for using this combination cream is a highly targeted and time-restricted regimen focused on topical administration to the affected areas of the face.


Administration Scope

Instruction Detail
Route of administration: Cutaneous (External Use Only).
Dosing schedule: A thin film is applied to the hyperpigmented area, including a small surrounding margin of normal-appearing skin.
Timing in relation to meals: Not applicable; application is generally timed for the evening or at least 30 minutes before bedtime.
Preparation requirements: The skin should be cleansed before application.
Age-group administration rules: Pediatric use is not established; use is not recommended for children under the age of 12 years.
Special procedural conditions: Treatment is for short-term use only and must be discontinued when control of the condition is achieved.

Instruction Classifications (High-Level)

Classification Detail
Administration method type: Topical (Cream).
Frequency pattern: Once daily (Fixed schedule).
Use-context constraints: Mandatory sun protection (sunscreen, protective clothing) is required during the day.

Connection to the Overall Use Protocol

The official instructions define a highly localized, time-constrained administration protocol, strictly limiting the route to cutaneous application and mandating a fixed once-daily evening schedule. This structure establishes a usage pattern centered on short-term intervention, with required co-administration steps, such as sun protection, integrated into the proper procedural sequence to ensure adherence to the standard of use. The treatment should not be covered with occlusive dressings unless specifically directed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Melacare PLUS

Evidence for Use in Moderate-to-Severe Facial Melasma

This section summarizes the clinical studies that have specifically evaluated the triple combination cream (containing hydroquinone, tretinoin, and a corticosteroid) for its primary studied indication: conditions involving persistent dark patches on the face. The summary details the types of Randomized Controlled Trials (RCTs) and systematic reviews that exist, as well as the objective methods (like the MASI score) researchers used to monitor the condition's parameters.

Research for this triple combination therapy was conducted in studies examining short-term or episodic symptom patterns associated with moderate-to-severe facial melasma. Randomized Controlled Trials (RCTs) are central to the evidence structure, where patients were observed over defined time intervals, typically around eight weeks. These trials focused on outcomes related to symptom intensity or variability, monitored using the Melasma Area and Severity Index (MASI).

Comparator Studies and Active Ingredients

The triple combination cream was evaluated in comparative research settings where one or more of the active ingredients were omitted from the preparation. These studies explored how the cream performed when compared to a combination of only two ingredients or against hydroquinone monotherapy. Data show patterns related to the differences measured in the MASI score when comparing the various formulations. This research provides context on how the combination of three ingredients was studied in relation to persistent discoloration.

What is Still Uncertain About Melacare PLUS Research

Research has explored the parameters over a defined short-term period, but the extent of long-term outcomes is not well characterized. Controlled data on long-term outcomes and maintenance over many years remains limited. Data show patterns related to symptom re-emergence (relapse) after the active treatment phase, but comparative evidence is lacking for optimal maintenance approaches.

Furthermore, the research applies primarily to the populations included in the trials. Data for certain groups remain insufficient; specifically, there is limited dedicated information for people with Fitzpatrick skin types V and VI (darker skin tones), as these populations were underrepresented in the primary trials. Research efforts continue to characterize these areas of uncertainty.

Frequently Asked Questions (FAQ)

Common questions about Melacare PLUS (FAQ)


Q: What is the main difference between Melacare PLUS and the regular Melacare cream?

A: The key difference is typically defined by the combination of active components and their concentrations. According to official composition data, 'Melacare PLUS' is a fixed-dose combination cream containing Hydroquinone, Tretinoin, and a corticosteroid, whereas other Melacare products may contain a different mix of ingredients. This formulation is specifically designed to use the three ingredients together for their intended purpose.


Q: How quickly do people usually notice changes after starting Melacare PLUS?

A: Official regulatory prescribing information indicates that users typically begin to see noticeable improvement within 4 to 8 weeks of consistent use. The period of treatment is usually prescribed for a short-term duration until the skin condition is controlled, as noted in official guidelines.


Q: Can Melacare PLUS be used on parts of the body other than the face?

A: Regulatory documents state that this cream is specifically indicated for the treatment of moderate to severe melasma of the face. The regulatory documents only indicate its use for melasma of the face and do not specify its application on other body areas.


Q: What happens if I forget to apply Melacare PLUS one night?

A: General guidance documented in patient information suggests that missed applications should be made up as soon as remembered, unless it is close to the next scheduled time. The official instruction is to avoid applying a double amount to compensate for a missed application.


Q: Are there any long-term safety concerns associated with using Melacare PLUS?

A: Yes, official safety documents highlight several potential concerns associated with using the cream for longer than the recommended short-term duration. These risks include potential skin atrophy (skin thinning), HPA axis suppression (an effect on the body's hormonal system from the steroid component), and a rare risk of Exogenous Ochronosis (a blue-black skin darkening) associated with hydroquinone.


Q: Can Melacare PLUS be used by people with sensitive skin?

A: Official information lists local reactions like redness, burning, and irritation as common side effects, especially when treatment is first started. Regulatory guidance suggests that individuals with pre-existing skin conditions or known sensitive skin types should use the cream with caution, as described in product information.


Q: Can Melacare PLUS be used safely during summer months?

A: Official regulatory guidance makes mandatory daily sun protection (using broad-spectrum sunscreen and protective clothing) a condition of use due to the risk of photosensitivity (increased sensitivity to light). The product label does not restrict use based on the season, as long as the mandatory sun protection measures detailed in the regulatory instructions are followed.


Q: What if I accidentally get Melacare PLUS in my eyes or mouth?

A: This cream is strictly for external use only. Official instructions state to avoid contact with the eyes, mouth, and other sensitive areas. If accidental contact occurs, the regulatory information suggests rinsing the area thoroughly with clean water immediately.


Q: Does Melacare PLUS have any known effects on pigmentation in darker skin tones?

A: Official research summaries indicate that individuals with Fitzpatrick skin types V and VI (darker skin tones) were underrepresented in the primary clinical trials. Furthermore, the rare risk of Exogenous Ochronosis (blue-black darkening) associated with the hydroquinone component is reported more frequently in individuals with darker skin.


Q: What is the likelihood of developing a severe allergic reaction to Melacare PLUS?

A: The cream is officially contraindicated (should not be used) in individuals with a known hypersensitivity to any of its components, which may include sulfites. Although rare, severe allergic reactions like asthma or breathing difficulty are documented as possible serious side effects in official documents.


Q: What happens if Melacare PLUS is used for longer than officially recommended?

A: Using the cream beyond the recommended short-term duration is associated with the documented risks of serious side effects. Official warnings highlight risks like skin thinning (atrophy) and the potential for the steroid component to cause adverse systemic effects on the body.


Q: What should I do if the skin irritation from Melacare PLUS does not go away?

A: While minor local irritation is common at the start of treatment, Official patient information states that a healthcare provider should be consulted if the irritation, burning, stinging, or redness persists, worsens, or becomes a cause for concern.


Q: Can Melacare PLUS be used to lighten freckles or moles?

A: The cream is officially indicated for the treatment of moderate to severe melasma of the face. Regulatory documents do not provide information on its specific use or effectiveness for treating other specific skin lesions like freckles or moles.


Q: Does Melacare PLUS help with acne scars or only with pigmentation issues?

A: The product is officially indicated for melasma, which is a pigmentation issue. While one component, Tretinoin, is used in other formulations to address skin concerns, regulatory documents for this specific combination cream do not list acne scars as an official indication.


Q: Is there scientific evidence supporting the long-term use of Melacare PLUS?

A: Official research summaries state that controlled data regarding the long-term safety and outcomes of using this triple combination cream over many years remains limited. The primary evidence focuses on short-term outcomes.


Q: Do any official documents describe potential withdrawal symptoms when discontinuing Melacare PLUS?

A: Regulatory documents do not use the term 'withdrawal symptoms' but do refer to the potential for relapse (the re-emergence of symptoms) after the active treatment phase is complete. This indicates that the skin condition may return following discontinuation.


Q: Can Melacare PLUS be used alongside prescription oral medications?

A: Due to the cream's topical nature, systemic absorption is low, meaning interactions are generally considered less likely than with oral medicines. Regulatory warnings state that a healthcare provider should be informed about all prescription oral medicines being used, due to theoretical concerns related to how the body metabolizes some of the cream's components.


Q: What kind of moisturizers are generally acceptable to use with Melacare PLUS?

A: Official warnings caution against using other topical products that cause additive irritation or drying effects. This list of substances to avoid includes alcohol, astringents, and abrasive ingredients, but regulatory documents do not explicitly name acceptable brands or types of moisturizers.


Q: Is the effect of Melacare PLUS on dark spots considered reversible?

A: Regulatory sources describe the skin-lightening effect of the hydroquinone component as potentially reversible. The discoloration may return, particularly if the cream is discontinued or if the skin is re-exposed to sunlight.


Q: Is it true that Melacare PLUS can cause a rebound effect if stopped suddenly?

A: Official research focuses on the issue of relapse, which is the re-emergence of symptoms after the treatment is discontinued. While the patient-focused term 'rebound effect' is not used in regulatory text, the data indicates that symptoms may return following discontinuation.


Q: Is Melacare PLUS available over the counter in some countries?

A: In countries with formal regulatory bodies that have approved this combination, it is classified as a prescription-only medicine (POM). This classification is due to the presence of both a corticosteroid and a retinoid, which officially require professional guidance for appropriate use.


Q: Is there a link between Melacare PLUS use and certain internal health conditions?

A: Official warnings advise caution for use in patients with pre-existing conditions affecting the liver or kidneys. The corticosteroid component also presents a documented risk of HPA axis suppression, which can affect the body's endocrine (hormonal) system.


Q: Can I use Melacare PLUS if I am taking oral contraceptives (birth control pills)?

A: Official labeling notes that melasma is often caused or worsened by hormonal changes, including those from birth control pills, and that women of child-bearing potential must use effective contraception during therapy. No systemic drug-drug interaction with oral contraceptives is specifically listed in the regulatory documents.


Q: Can I use Melacare PLUS if I have diabetes?

A: Official warnings note that the systemic absorption of the corticosteroid component may potentially affect the endocrine system. The use of the cream in individuals with conditions like diabetes is described as requiring caution.


Q: Can I apply the cream right after shaving or hair removal?

A: Regulatory documents state that application should occur only on healthy, intact skin surfaces. Application on skin that is cut, bruised, infected, or freshly irritated (such as from recent shaving or hair removal) is generally noted as being advised against.


Q: Is Melacare PLUS safe to use while breastfeeding?

A: Official documents state that it is unknown if the components are passed into human milk following topical application. Use while breastfeeding is described in regulatory documents as requiring professional guidance.

How should Melacare PLUS be stored and disposed of?

This topical cream must be stored and handled according to the instructions provided in the official labeling to maintain its stability and effectiveness.

Official Storage Requirements

Condition Regulatory Rule
Temperature Store at room temperature, typically below 30 C or 77 F.
Protection Keep the cream in a dry place and protected from light and excessive heat.
Handling Keep from freezing and ensure the container is tightly closed when not in use.

Disposal and Safety Rules

  • Child Safety: It is a mandatory requirement to keep this medicine out of the sight and reach of children and pets.
  • Disposal: Unused or expired medication must be disposed of according to local pharmaceutical disposal guidelines. The cream must not be flushed down a toilet or sink, or discarded into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Melacare PLUS found in:

A-Z Index: